Core One Labs Granted Management Cease Trade Order

Vancouver, British Columbia--(Newsfile Corp. - June 12, 2020) - Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD61) (WKN: A14XHT) ("COOL" or the "Company") announced today that the British Columbia Securities Commission has granted the Company's request for a management cease trade order (the "MCTO"). As previously announced, the application for the MCTO was made by the Company in connection with the anticipated delay in the filing its financial statements for the year ended December 31, 2019 and the related management's discussion and analysis ("MD&A") and certifications (the "Annual Filings").

As previously disclosed, the Company requires additional time to complete the Annual Filings, including the audit of the Company's consolidated financial statements for the year ended December 31, 2019. The Company will work with its auditors to complete the audit of the Company's financial statements, and to file the Annual Filings, by July 15, 2020.

During the period during which the MCTO is in effect, the general investing public will continue to be able to trade in the Company's securities. However, for the duration of the MCTO, the Company's Chief Executive Officer will not be able to trade in the Company's common shares. The Company does not currently have a chief financial officer, and is currently in the process of seeking and evaluating suitable candidates. However, this process has also been hampered by COVID-19 related complications. The Company has also imposed an insider trading blackout pending filing of the Annual Filings. The Company will comply with the alternative information guidelines set forth in NP 12-203 for so long as it remains in default of the requirement to file the Annual Filings. The MCTO will remain in effect until the Company files the Annual Filings or the MCTO is otherwise revoked or varied.

About Core One Labs Inc.

Core One Labs Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The Company's technology produces infused strips (like breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. Some strips will also include supplemental co-active ingredients such as nutraceuticals, vitamins and peptides. The technology provides a new way to accurately meter the dosage and assure the purity of selected product. From start to finish, the production process, based on the Company's technology, tests for quality and composition of all the ingredients used in every strip which results in a delivery system that is safe, consistent and effective. In addition, through its efforts to develop a better CannaStripsTM product, the Company has developed considerable expertise in cannabis extraction and nursery activities. The operational expertise developed by the Company as a result of these efforts has created new market opportunities for the Company in white label sales.

Core One Labs Inc.
Brad Eckenweiler
CEO & Director

FOR MORE INFORMATION, PLEASE CONTACT:
InvestorRelations@coreonelabs.ca
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57767

info